Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia

Anna Lucia Fedullo, Monica Messina, Loredana Elia, Alfonso Piciocchi, Valentina Gianfelici, Alessia Lauretti, Stefano Soddu, Maria Cristina Puzzolo, Clara Minotti, Felicetto Ferrara, Bruno Martino, Patrizia Chiusolo, Valeria Calafiore, Stefania Paolini, Marco Vignetti, Antonella Vitale, Anna Guarini, Robin Foà and Sabina Chiaretti

1Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome; 2GIMEMA Data Center, Rome; 3Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples; 4Hematology Unit, Azienda Ospedaliera Bianchi Melacrinio Morelli, Reggio Calabria; 5Institute of Hematology, Catholic University, Rome; 6Division of Hematology, AOU Policlinico, University of Catania; "L. and A. Seràgnoli" Institute of Hematology, University of Bologna and 7Department of Molecular Medicine, Sapienza University, Rome, Italy

*These authors contributed equally to this work

ABSTRACT

To shed light onto the molecular basis of Philadelphia chromosome-positive acute lymphoblastic leukemia and to investigate the prognostic role of additional genomic lesions, we analyzed copy number aberrations using the Cytoscan HD Array in 116 newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia enrolled in four different GIMEMA protocols, all based on a chemotherapy-free induction strategy. This analysis showed that patients with Philadelphia chromosome-positive acute lymphoblastic leukemia carry an average of 7.8 lesions/case, with deletions outnumbering gains (88% versus 12%). The most common deletions were those targeting IKZF1, PAX5 and CDKN2A/B, which were detected in 84%, 36% and 32% of cases, respectively. Patients carrying simultaneous deletions of IKZF1 plus CDKN2A/B and/or PAX5 had a significantly lower disease-free survival rate (24.9% versus 43.3%; P = 0.026). The only IKZF1 isoform affecting prognosis was the dominant negative one (P = 0.003). Analysis of copy number aberrations showed that 18% of patients harbored MEF2C deletions, which were of two types, differing in size: the longer deletions were associated with the achievement of a complete molecular remission (P = 0.05) and had a favorable impact on disease-free survival (64.3% versus 32.1% at 36 months; P = 0.031). These findings retained statistical significance also in multivariate analysis (P = 0.057). KRAS deletions, detected in 6% of cases, were associated with the achievement of a complete molecular remission (P = 0.009). These results indicate that in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia a detailed evaluation of additional deletions - including CDKN2A/B, PAX5, IKZF1, MEF2C and KRAS - has prognostic implications and should be incorporated in the design of more personalized treatment strategies.

Introduction

The Philadelphia (Ph) chromosome derives from the t(9;22)(q34;q11) and leads to a BCR-ABL1 rearrangement. The incidence of this chromosomal change in acute lymphoblastic leukemia (ALL) increases with age, being detected in 25% of adults and in about 50% of elderly patients. Prior to the advent of tyrosine kinase inhibitors, the outcome of Ph+ ALL patients was extremely poor, and the only
possibility of a cure was allogeneic stem cell transplantation (HSCT), when feasible. The introduction of tyrosine kinase inhibitors, administered with low doses or without chemotherapy during induction, followed by consolidation chemotherapy and HSCT has markedly improved the management and outcome of adult Ph+ ALL patients, with survival rates at 5 years now approaching 50%.6-17

Different biological features - the type of fusion transcript (i.e. p190 or p210),18 the persistence and/or reappearance of minimal residual disease (MRD),19,20 additional genomic deletions (particularly IKZF1, and to a lesser extent CDKN2A/B and PAX5),21-24 - and the presence of mutations at relapse are associated with a worse outcome.25-27 However, a broad and refined biological algorithm that could help to optimize treatment strategies and define better whether some patients could be spared intensive treatment, including HSCT, has so far not been proposed.

To this end, in the present study we investigated copy number aberrations (CNA) in 116 newly diagnosed adult Ph+ ALL patients to identify additional molecular lesions with the aim of improving patients’ stratification and management.

Methods

Experimental strategy

Bone marrow and/or peripheral blood samples from 116 patients (Table 1) with newly diagnosed Ph+ ALL enrolled in four GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) trials were analyzed (Online Supplementary Table S1). The study was carried out in four phases (Online Supplementary Figure S4): (i) CNA analysis of 116 samples by CytoScan; (ii) multiplex ligation-dependent probe amplification analysis; (iii) validation of ME2FC deletions by digital droplet (dd) polymerase chain reaction (PCR); and (iv) ME2C and KRAS mutational screening.

This study was approved in the context of an Associazione Italiana per la Ricerca sul Cancro (AIRC) project (10007) with Institutional Review Board number 2182/16.06.2011.

Copy number aberration analysis

CNA were analyzed using CytoScan® HD Arrays (Affymetrix, Santa Clara, CA, USA) and Chromosome Analysis Suite (ChAS) software. Germline material from five paired samples was also evaluated. Recurrent deletions were validated with the Salsa MLPA P335 ALL-IKZF1 kit (MRC-Holland, Amsterdam, the Netherlands)28,29 (Online Supplementary Data). Statistical analyses on clinical correlates are described in the Online Supplementary Data.

Table 1. Patients’ clinical features.

| Feature                                      | Patients (n=116) |
|----------------------------------------------|-----------------|
| Gender (male/female)                         | 55/61           |
| Age, years (range)                           | 51.1 (18.9-89)  |
| Median white cell count x 10^9/L (range)     | 25.4 (1.7-597)  |
| Median hemoglobin g/dL (range)               | 9.6 (4-16.3)    |
| Median platelet count x 10^9/L (range)       | 50 (4-333)      |
| Fusion transcript (p190/p210/p190-210)*       | 70/29/16        |
| Complete molecular response* yes/no          | 17/99           |

*As per protocol definition; *information missing for one patient.

Digital droplet polymerase chain reaction assays

ME2FC deletions were validated by ddPCR using the OX200™ Droplet Digital™ PCR System (BioRad, Hercules, CA, USA) and QuantaSoft Analysis Pro software according to the manufacturer’s instructions (Online Supplementary Data).

Mutational screening

Sanger sequencing of PCR products for ME2FC and KRAS exons (Online Supplementary Table S2) was performed with the ABI-Prism 3500 sequencer (Applied Biosystem, Life Technologies, Foster City, CA, USA) (Online Supplementary Data).

Results

Copy number aberration analysis

CNA analysis revealed 7.8 aberrations/patient (range: 0-28), the majority being losses (88%) with only 12% gains, both spanning from whole chromosomes to focal lesions;22,23,30,31 no differences were recorded among trials (Figure 1A).

Gross chromosomal lesions were found in 42% of cases: the majority were losses of chromosome 7 (18.1%), followed by monosomy of chromosome 9 or 9p deletion (9%) and gain of 1q (7.7%) (Figure 1B, Online Supplementary Table S3). Smaller deletions - limited to one or three genes and defined as focal - were found in 56% of cases.

The most frequently deleted region involved the 7p12 cytoband comprising IKZF1,22,23,33,34 which was detected in 97 cases (84%).

PAX5 was deleted in 43 patients (36.2%), while 37 (31.9%) had deletions of CDKN2A/B. MLLT3, BTG1, BTLA, CD200 and RB1 were deleted in 30, 27, 21, 17 and 16 cases, respectively (25.9%, 23%, 18.1%, 17.2%, 14.6%, and 13.8%) (Figure 1C).

IKZF1 deletions (ΔIKZF1) occurred together with CDKN2A/B and/or PAX5 deletions in 45/97 cases (46.4%) and are defined as ΔIKZF1+CDKN2A and/or PAX5 (Figure 1D); this subset displayed similar lesions to those recently described by Stanulla and colleagues.35 With regard to potential interactions, we found a significant association between ΔIKZF1 and PAX5 deletions (P=0.01), but not with CDKN2A.

Multiplex ligation-dependent probe amplification confirmed IKZF1, PAX5, CDKN2A, BTG1, EBF1, ETV6 and RB1 lesions, and allowed evaluation of IKZF1 isoforms. These isoforms were grouped into four classes:21,36 wild-type, dominant-negative (comprising Δ4-7 cases, 29.8%), haploinsufficient (including all cases harboring a deletion that involves exon 2 - i.e. Δ2-7, Δ2-8, Δ2-3, Δ1-3 - or the whole gene, 57.7%) and miscellaneous (remaining cases, 11.3%).

Identification of novel lesions

CNA analysis highlighted additional genomic lesions (Table 2, Online Supplementary Table S4). We focused in particular on ME2FC and KRAS deletions since these had prognostic significance (see below). ME2FC deletions were detected in 21 patients (18.1%) and differed in size. According to the length of intron 1-2 losses, deletions were grouped into two categories. One category - detected in 14 cases (67% of ME2FC deleted cases) - was characterized by a larger minimal common region (6.2 Kb) involving introns 1-2 and exon 2 (the first codifying exon),
defined ΔMEF2C-long. The other category, detected in seven patients, was smaller (5.4 Kb) and involved only exon 2, and was called ΔMEF2C-short (Figure 2A). ddPCR confirmed MEF2C lesions in all cases. No MEF2C mutations were identified.

KRAS deletions (ΔKRAS) were detected in seven cases (6%); the focal lesion of KRAS started in the 5’ untranslated region and ended in intron 1-2, involving the first non-codifying exon (Figure 2B). The minimal common region consisted of 135 Kb. KRAS was not affected by mutations.

Impact of known and novel deletions on complete molecular response achievement and disease-free survival

We did not find significant differences between patients with ΔIKZF1 and IKZF1 wild-type cases with regard to achievement of complete molecular response (CMR) or disease-free survival (DFS) (Online Supplementary Figure S2). Further stratification according to IKZF1 isoforms showed that patients with the dominant-negative isoform had a lower DFS rate (23.3%; $P=0.039$) compared to patients with the other isoforms, particularly wild-type (53.3%; $P=0.016$) and haploinsufficient cases (40.3%; $P=0.015$); the DFS rate of the miscellaneous group (34.1%) did not differ significantly from that of the dominant-negative cases (Figure 3A). These differences were not statistically significant in the overall survival analysis (Figure 3B).

We also investigated the outcome of ΔIKZF1+CDKN2A and/or PAX5 cases. The CMR rate did not differ between ΔIKZF1+CDKN2A and/or PAX5 and ΔIKZF1-only cases; contrariwise, ΔIKZF1+CDKN2A and/or PAX5 patients had a significantly worse DFS than ΔIKZF1-only cases (43.3% versus 24.9%; $P=0.026$) (Figure 3C) and an inferior overall survival (62.6% versus 40.2%; $P=0.02$) (Figure 3D).

The presence of ΔMEF2C-long was associated with a higher rate of CMR achievement ($P=0.05$); this effect was not influenced by the protocol or the tyrosine kinase inhibitor used (imatinib or dasatinib). Furthermore, ΔMEF2C-long cases were also associated with a signifi-

---

**Table 2. Minimal common region (MCR) of identified focal lesions.**

| Deleted gene | N. of patients (%) | MCR (hg19) |
|--------------|-------------------|------------|
| FOCAD        | 29 (25)           | chr9: 20685149 - 20759956 |
| CDK6         | 24 (20.7)         | chr7: 92456635 - 92566647 |
| PTPRD        | 21 (18.1)         | chr9: 81593932 - 8164489 |
| MEF2C        | 21 (18.1)         | chr3: 580122179 - 580127630 |
| BTLA         | 21 (18.1)         | chr5: 112154702 - 112217769 |
| JAK2         | 20 (17.2)         | chr5: 5123013 - 51234403 |
| ADD3         | 18 (15.5)         | chr10: 11175029 - 111853867 |
| SLXHPI       | 17 (14.6)         | chr20: 10417444 - 10451891 |
| CD200        | 17 (14.6)         | chr6: 112054292 - 112054292 |
| HBSIL        | 16 (13.7)         | chr6: 135373338 - 135418257 |
| APT10A       | 14 (12)           | chr6: 20805558 - 20805558 |
| TOX          | 8 (6.9)           | chr8: 60028851 - 60018235 |
| KRAS         | 7 (5)             | chr12: 25402194 - 25537468 |
| ARHGAP24     | 7 (5)             | chr12: 84693655 - 84693655 |
| EBFI         | 6 (5.1)           | chr15: 158440156 - 158440156 |
| LEFI         | 5 (4.3)           | chr16: 10904332 - 10904332 |
| MDM2         | 5 (4.3)           | chr12: 69159076 - 69205287 |
| TCF12        | 4 (3.4)           | chr15: 57399047 - 57399047 |
| ERG          | 2 (1.7)           | chr21: 39772775 - 39788683 |

---

**Figure 1.** Overall load and incidence of genetic lesions in Philadelphia chromosome-positive acute lymphoblastic leukemia. (A) Distribution of copy number aberrations in the whole cohort and across different protocols. (B) Percentages of gross chromosomal aberrations. (C) Percentages of deletions of known genes in the whole cohort (n=116) and in the different studies analyzed. (D) Heatmap of IKZF1, CDKN2A/B, and PAX5 deletions in the whole cohort.
significant better DFS (64.3% versus 32.1%; \(P=0.031\)) (Figure 4A) and overall survival (77.9% versus 48.4%; \(P=0.036\)) (Figure 4B).

Lastly, \(\Delta KRAS\) was more frequently found in patients who obtained a CMR (24% versus 3%; \(P=0.009\)), but this finding did not have an impact on DFS.

Prognostic impact of known and novel genomic lesions in univariate and multivariate analyses

In univariate analysis, \(\Delta MEF2C\)-long and \(\Delta KRAS\) had an impact on CMR achievement, while \(\Delta MEF2C\)-long and \(\Delta IKZF1+CDKN2A\) and/or \(PAX5\) influenced DFS (Table 3).

In multivariate analysis for CMR, performed taking into account...
account white blood cell count, age, tyrosine kinase inhibitor use and the genomic lesions described above, the only factor that retained statistical significance was ΔKRAS (P = 0.01); a trend was noted for ΔMEF2C-long deletions (P = 0.075) (Table 3).

In multivariate analysis for DFS, considering ΔMEF2C-long, ΔIKZF1+CDKN2A and/or PAX5, white blood cell count and CMR as variables, the factors that had a negative impact were ΔMEF2C-long (P = 0.057) and white blood cell count (P = 0.05), while a trend towards a worse DFS was observed for ΔIKZF1+CDKN2A and/or PAX5 (P = 0.089) (Table 3). HSCT did not affect the prognostic role of the above-mentioned lesions.

### Discussion

The management of adults with Ph+ ALL currently relies on the use of first-generation, second-generation and third-generation tyrosine kinase inhibitors, either alone or in combination with chemotherapy, followed if feasible by HSCT. These approaches have greatly improved the outcome of Ph+ ALL: nowadays, virtually all patients - independent of age - achieve a complete hematologic remission, coupled to a CMR in a variable proportion of cases. Nonetheless, in all reported studies the long-term outcome is in the range of 50% at 5 years; thus, additional prognosticators capable of better stratify-

### Table 3. Summary of univariate and multivariate analyses for complete molecular response and disease-free survival for the factors identified.

| Factor                                | Univariate analysis for CMR OR (95% CI) | P value | Multivariate analysis for CMR OR (95% CI) | P value |
|---------------------------------------|----------------------------------------|---------|------------------------------------------|---------|
| MEF2C deletions                       | 0.288 (0.082, 1.007)                   | 0.051   | 0.259 (0.058, 1.146)                     | 0.075   |
| KRAS deletions                        | 0.12 (0.024, 0.601)                    | 0.009   | 0.068 (0.009, 0.529)                     | 0.01    |
| White blood cell count                | 0.986 (0.969, 1.003)                   | 0.1     | 0.986 (0.966, 1.007)                     | 0.188   |
| Age                                   | 1.026 (0.99, 1.063)                    | 0.16    | 1.028 (0.985, 1.072)                     | 0.205   |
| Imatinib vs. dasatinib                | 0.267 (0.057, 1.248)                   | 0.093   | 0.296 (0.054, 1.615)                     | 0.159   |
| Fusion protein (p190 vs. p210 and p190/210) | 1.247 (0.421, 3.693)                  | 0.691   |                                          |         |
| ΔIKZF1+CDKN2A and/or PAX5             | 1.600 (0.599, 4.581)                   | 0.381   |                                          |         |

| Factor                                | Univariate analysis for DFS HR (95% CI) | P value | Multivariate analysis for DFS HR (95% CI) | P value |
|---------------------------------------|----------------------------------------|---------|------------------------------------------|---------|
| MEF2C deletions                       | 0.559 (0.144, 0.891)                   | 0.027   | 0.417 (0.169-1.028)                      | 0.067   |
| ΔIKZF1+CDKN2A and/or PAX5             | 1.834 (1.148, 2.929)                   | 0.011   | 1.608 (0.930, 2.781)                     | 0.089   |
| White blood cell count                | 1.002 (1.1004)                        | 0.065   | 1.003 (1.1006)                           | 0.050   |
| Age                                   | 1.001 (0.986, 1.017)                   | 0.866   | 1.01 (0.985-1.028)                       | 0.180   |
| CMR                                   | 0.423 (0.181-0.987)                   | 0.046   | 0.402 (0.167-0.969)                      | 0.042   |
| Fusion protein (p190 vs. p210 and p190/210) | 0.939 (0.582, 1.515)                  | 0.797   |                                          |         |
| Imatinib vs. dasatinib                | 1.305 (0.807, 2.109)                   | 0.277   |                                          |         |
| Allogeneic transplant                 | 0.882 (0.362, 2.284)                   | 0.23    |                                          |         |

CMR: complete molecular response; OR: odds ratio; 95% CI: 95% confidence interval; DFS: disease-free survival; HR: hazard ratio.

---

![Figure 4](image-url) **Figure 4.** Survival probability curves according to MEF2C status. (A) Disease-free survival at 36 months of ΔMEF2C versus MEF2C wild-type patients. (B) Overall survival at 36 months of ΔMEF2C versus MEF2C wild-type patients. WT: wild-type; DFS: disease-free survival; OS: overall survival; CR: complete remission.
ing patients into high- and low-risk categories are urgently needed to further optimize treatment. Moreover, another unsolved issue is whether all eligible patients should undergo HSCT, a procedure still associated with short- and long-term side effects, as well as treatment-related mortality. This is particularly important for patients who obtain a CMR.

To address these issues we sought to identify additional genomic lesions with prognostic significance in adult Ph+ ALL using high density Cytoscan arrays. We found that adult Ph+ ALL patients carried an average of 7.8 aberrations each, with deletions outnumbering gains, in line with other ALL subsets. Macro-aberrations were identified in 48% of cases and micro-aberrations in the majority of patients: among the latter, the most frequent was ΔIKZF1, which was detected in 84% of cases. ΔIKZF1 has been regarded as a poor prognostic marker in both childhood and adult ALL. This finding was not, however, confirmed in our cohort: in fact, the presence of ΔIKZF1 alone was not associated with a worse DFS. A further evaluation of the various IKZF1 isoforms showed that only the dominant-negative genotype was deleterious for outcome. In addition, patients with ΔIKZF1+CDKN2A and/or PAX5, accounting for almost half the ΔIKZF1 cases, experienced a significantly inferior DFS (P=0.005) and overall survival (P=0.02), in line with previous reports on ALL in general. ΔIKZF1+CDKN2A and/or PAX5 also had a prognostic impact in multivariate analysis; survival analysis was carried out merging all cases enrolled in the different trials together in order to gain statistical significance.

Recently, studies have been focused on the presence of additional karyotypic aberrations in Ph+ ALL. These studies have highlighted that a high percentage of Ph+ ALL cases (60-80%) harbor additional chromosomal abnormalities, with the most frequent aberrations involving chromosomes 7, 9, and 14. Patients with additional abnormalities, particularly loss of 9p9p and/or CDKN2A, have a worse outcome. These results point to the importance of screening for other molecular markers, and not only IKZF1, in agreement with our findings on ΔIKZF1+CDKN2A and/or PAX5. At variance from these reports, our study also identified novel lesions that had a favorable impact on outcome. Among these, it is worth mentioning ΔMEF2C, which occurred in 18.1% of patients and was of two sizes, a long deletion, encompassing introns 1-2 and exon 2, and a second, smaller one, involving only exon 2. ΔMEF2C is a transcription factor involved in B-cell survival and proliferation whose overexpression is associated with an unfavorable prognosis in T-ALL and acute myeloid leukemia. In our study, the presence of ΔMEF2C-long was associated with achievement of a CMR (P=0.05) and with a significantly better DFS compared to the remaining cases (P=0.031) in a multivariate model; as for IKZF1 deletions, survival analysis was performed merging the whole cohort because of the sample sizes. ΔMEF2C-long was widely distributed among cases, with no association with white blood cell count, age, type of fusion protein or additional deletions. To our knowledge, this is the first report that correlates ΔMEF2C-long with prognosis in Ph+ ALL: Martinelli et al. described ΔMEF2C in Ph+ ALL, but did not demonstrate a correlation with outcome. Finally, ΔKRAS was associated with a higher rate of CMR achievement upon induction (P=0.01), but not with a better DFS.

In conclusion, we show that additional genetic lesions can be found at presentation in adult Ph+ ALL patients and that these lesions have prognostic significance, with the ΔMEF2C dominant-negative isoform and ΔIKZF1+CDKN2A and/or PAX5 negatively affecting outcome, and ΔMEF2C and ΔKRAS being instead associated with a more favorable prognosis. Screening for these genetic lesions should, therefore, be performed at the time of diagnosis for a more refined prognostic stratification, and for a more personalized and tailored management of Ph+ ALL patients.

Acknowledgments

The authors thank Associazione Italiana per la Ricerca sul Cancro (AIRC), Special Program Molecular Clinical Oncology-Extension program, 5 x 1000 (10007), Milan (Italy) for funding RF; Finanziamento per l’avvio alla ricerca 2015 (Sapienza University of Rome) for funding MM; Finanziamento Medi Progetti Universitari 2015 for funding SC (Sapienza University of Rome); and Fondazione Le Molinette Onlus, Turin (Italy).

References

1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85-109.
2. Chiaretti S, Vitale A, Cazzaniga G, et al. Clinicobiological features of 502 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98(11):1702-1710.
3. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357-2366.
4. Gleissner B, Gökbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1565-1568.
5. Pulkkinen V, Slovak ML, Kopecky KJ, et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111(5):2563-2572.
6. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allelogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104(10):3028-3037.
7. Patel JN, Druhan LJ. Genetic effects on hematopoietic stem cell transplant prognosis and outcomes, more than just histocompatibility. Blood. 2017;129(12):1227-1228.
8. de Labarthe A, Rousselet F, Huguet-Rigal F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109(4):1408-1413.
9. Vignetti M, Fazi P, Cirimin G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676-3678.
10. Chiaretti S, Vitale A, Vignetti M, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia. Final results of the GIMEMA LAL0904 study. Haematologica. 2016;101(12):1544-1552.
11. Foss B, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-6528.

12. Chinoy RJ, Caneva A, Elia L, et al. Multicenter Total Therapy GIMEMA LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification. Blood. 2013;126(25):e58.

13. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-based imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 0900. J Clin Oncol. 2010;28(22):3644-3652.

14. Sibler JM, Garcia O, Montesinos F, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukemia using increased dose of imatinib and intensified chemotherapy before autologous stem cell transplantation. Br J Haematol. 2012;159(1):78-81.

15. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2010;116(2):37-50.

16. Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia: results of the French acute leukemia in adults: Bone Marrow Transplant. 2017;52(12):1592-1598.

17. Cinzio G, Pane F, Elia L, et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica. 2006;91(5):577-580.

18. Lee S, Kim DW, Cho BS, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26(11):2367-2374.

19. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-negative ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214-1212.

20. Martineelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202-5207.

21. Mullighan CG, Miller CR, Radtke I, et al. BCR-ABL1 lymphoblastic leukemia is characterized by the deletion of Ikaros. Nature. 2007;446(7137):758-764.

22. Mullighan CG, Seol CA, Cho YU, Jang S, et al. Prognostic significance of recurrent additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy. Ann Hematol. 2009;88(11):1069-1077.

23. Seol CA, Cho YU, Jang S, et al. Prognostic significance of recurrent additional chromosomal abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Genet. 2013;217(21):217-25.

24. Mottola C, Ribera JM, Morgades M, et al. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017;92(3):258-260.

25. Heerema NA, Harbott J, Galimberti S, et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004;18(1):692-702.

26. Xu T, Chu L, Zou D, et al. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy. Ann Hematol. 2009;88(11):1069-1077.

27. Morfou C, Ribera JM, Morgades M, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential driver genes in pediatric T-cell lymphoblastic leukemia. Cancer Cell. 2011;19(4):484-497.

28. Zurbair I, Gutierrez A, Mullighan CG, et al. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica. 2014;99(1):94-102.

29. Sanzio GS, Alonzo TA, Gudgeon CJ, et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Childhood Acute Myeloid Leukemia Study. Cancer. 2014;121(21):3809-3817.

30. Comolli L, Ribera JM, Pannell R, et al. MEF2C-disregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN2A deletion and a glucocorticoid response to leukemia therapy. Leuk Lymphoma. 2015;57(12):2895-2904.